BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34301453)

  • 1. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
    Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
    Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
    Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
    Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
    Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
    Lee IH; Chen GY; Chien CR; Cheng JC; Chen JL; Yang WC; Chen JS; Hsu FM
    J Formos Med Assoc; 2021 Dec; 120(12):2176-2185. PubMed ID: 33451864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
    Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
    Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.
    Shirvani SM; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Smith BD
    JAMA Surg; 2014 Dec; 149(12):1244-53. PubMed ID: 25321323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.